Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar Magnesium in Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT05045482Phase 1Recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of saroglitazar magnesium in cholestatic liver disease (CLD) (2 arms), sponsored by Zydus Therapeutics. Primary endpoints: Pharmacokinetics of Saroglitazar at Day 28, Safety and Tolerability of Saroglitazar at 9 weeks and 3 more. Started Oct 2021; status: recruiting.
02
Drugs
saroglitazar magnesium
03
Conditions
cholestatic liver disease (CLD)
Beyond the preview
Go deeper on NCT05045482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045482.